Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibition of platelet aggregation using Anti-human gpvi antibodies

A technology of antibody molecules and uses, which is applied in the field of cardiovascular disease treatment and can solve problems such as being uncontrollable

Pending Publication Date: 2019-11-22
ACTICOR BIOTECH +4
View PDF23 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] However, GPVI depletion is undesirable because it cannot be controlled and is irreversible (i.e. it persists for the lifetime of the platelet, or even longer due to GPVI depletion on megakaryocytes)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibition of platelet aggregation using Anti-human gpvi antibodies
  • Inhibition of platelet aggregation using Anti-human gpvi antibodies
  • Inhibition of platelet aggregation using Anti-human gpvi antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0431] Example 1: Biological data of non-human primates

[0432] Materials and methods

[0433] animal

[0434] Twenty-eight cynomolgus monkeys without any prior treatment were used in this study.

[0435] deal with

[0436] First, increasing doses of ACT017 (1, 2, 4, 8 mg / kg) or its vehicle (n=4-8) were administered intravenously for 15 minutes. Blood was collected 30 minutes and 2 hours after administration.

[0437] In a second experiment, ACT017 was administered to animals by bolus injection or infusion. Three treatment groups were included in the study: ACT017 at 8 mg / kg (n=4) administered by 25-minute bolus injection, ACT017 at 8 mg / kg (n=8) administered by 1-hour infusion, and ACT017 administered by 15-minute bolus injection ACT017 was administered at 2 mg / kg followed by ACT017 at 6 mg / kg infusion over 5 hours and 45 minutes (n=4). Blood was collected at various times (20 minutes to 24 hours after administration).

[0438] analyze

[0439] Platelet Aggregation: ...

Embodiment 2

[0453] Example 2: Study on the safety, tolerance, pharmacokinetics and pharmacodynamics of ACT017 in healthy volunteers

[0454] Materials and methods

[0455] This study is a randomized, double-blind and placebo-controlled ascending single-dose study on the safety, tolerability, pharmacokinetics and pharmacodynamics of ACT017 in healthy volunteers. subjects

[0456] Subjects involved in the study were healthy male or non-pregnant, non-lactating female subjects, aged between 30 and 60 years (inclusive), with a BMI ≥ 18kg / m2 and ≤ 30kg / m2. A total of 48 subjects participated in 6 ascending dose level cohorts, each cohort consisted of 8 subjects: 6 received active and 2 received placebo. Each cohort was divided into 2 subgroups: one at the start of dosing (1 active and 1 placebo) and the other 48 hours thereafter (5 active and 1 placebo).

[0457] On Day -1 of each dosing period, subjects entered the study center and remained there until at least 48 hours post-dose. Follow-up ...

Embodiment 3

[0482] Example 3: Research on the Epitope Affinity of ACT017 to GPVI

[0483] The ACT017 epitope on GPVI was previously identified by epitope mapping as a conformational epitope comprising two regions on GPVI: amino acids 121-135 and amino acids 169-183 in SEQ ID NO:13. To validate this epitope, a double mutant was constructed containing the following mutations: S125P, S126Q, G128R, Q133K, T136S, T171D, A172L, and H174V, and the affinity of this mutant to collagen and ACT017 was measured.

[0484] Materials and methods

[0485] Soluble GPVI-Fc was produced as follows: after codon optimization, the gene encoding the extracellular domain of human GPVI from the first methionine to asparagine 269 was synthesized by the tripeptide GGR with the human IgG1 Fc structure domain fusion. The gene was cloned into pTT5 vector and then transfected into HEK 293-6E cells. The secreted GPVI-Fc was purified from the conditioned medium of cells by affinity chromatography using MAbselect matri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI ) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Description

[0001] field of invention [0002] The present invention relates to the treatment of cardiovascular diseases. In particular, the invention relates to methods of treating cardiovascular disease comprising the continuous administration of novel anti-human glycoprotein VI antibodies or fragments thereof to human patients in need thereof. [0003] Background of the invention [0004] Acute coronary and cerebrovascular events are currently the leading causes of death in the world. Furthermore, the global incidence of relapse and death in the post-treatment 6-month cycle after acute coronary syndrome remains 8-15%. [0005] In the case of acute coronary syndrome with ST-segment elevation, mechanical treatment with coronary angioplasty and introduction of a stent is highly effective for urgent restoration of coronary blood flow, but does not prevent the subsequent 6-month Morbidity / mortality in approximately 15% of patients. Thrombolytic therapy based on a combination of long-term ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61K39/395A61K39/00
CPCA61K39/39541A61K39/3955C07K16/2803A61K2039/505A61K2039/54A61K2039/545C07K2317/24C07K2317/55C07K2317/76A61P9/00C07K2317/92C12N9/6459A61P7/02C12Y304/21068A61K9/0019C07K2317/34C07K2317/565
Inventor P·比亚阿多M·扬德特-佩吕G·阿弗纳尔
Owner ACTICOR BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com